论文部分内容阅读
目的:探讨核呼吸因子-1(NRF-1)蛋白表达与乳腺癌发生发展、临床病理特征及Ki-67的关系。方法:采用免疫组化EnVision二步法,对211例乳腺癌组织、50例乳腺良性病变组织中NRF-1和Ki-67进行检测。结果:NRF-1表达定位于细胞核,在乳腺癌中表达率为87.2%,低于乳腺良性病变组织的100%(χ~2=100.288,P<0.001);高分化乳腺癌NRF-1表达率明显高于中、低分化乳腺癌(χ~2=16.242,P=0.001;χ~2=72.802,P<0.001),中分化乳腺癌也明显高于低分化乳腺癌(χ~2=30.190,P=0.000)。乳腺癌淋巴结转移患者NRF-1表达率明显低于未转移者(χ~2=12.025,P=0.007);TNM分期中Ⅰ期NRF-1表达率明显高于Ⅱ、Ⅲ期(χ~2=12.025,P=0.007)。211例乳腺癌中Ki-67表达率为78.7%,Ki-67表达与NRF-1(χ~2=42.914,P<0.001)、病理组织学分级(χ~2=40.239,P<0.001)、淋巴结转移(χ~2=16.061,P=0.001)和TNM分期(χ~2=13.589,P=0.004)间比较差异有统计学意义。结论:NRF-1参与了乳腺癌的发生发展,也与Ki-67表达有相关性,可作为乳腺癌患者疾病进展监控和预后观测的指标,有可能成为乳腺癌新的治疗靶点。
Objective: To investigate the relationship between the expression of nuclear respiratory factor-1 (NRF-1) protein and the development of breast cancer, clinicopathological features and Ki-67. Methods: The immunohistochemical EnVision two-step method was used to detect the expression of NRF-1 and Ki-67 in 211 cases of breast cancer and 50 cases of benign breast lesions. Results: The expression of NRF-1 localized in the nucleus and the expression rate of NRF-1 in breast cancer was 87.2%, lower than that in benign breast lesions (χ ~ 2 = 100.288, P <0.001) (Χ ~ 2 = 16.242, P = 0.001; χ ~ 2 = 72.802, P <0.001), moderately differentiated breast cancer was also significantly higher than that of poorly differentiated breast cancer (χ ~ 2 = 30.190, P = 0.000). The expression of NRF-1 in patients with lymph node metastasis of breast cancer was significantly lower than those without metastasis (χ ~ 2 = 12.025, P = 0.007). The expression of NRF-1 in stage Ⅰ was significantly higher than that in stage Ⅱ and Ⅲ 12.025, P = 0.007). The expression of Ki-67 in 211 cases of breast cancer was 78.7%, the expression of Ki-67 was significantly higher than that of NRF-1 (χ ~ 2 = 42.914, P <0.001) There was significant difference between lymph node metastasis (χ ~ 2 = 16.061, P = 0.001) and TNM stage (χ ~ 2 = 13.589, P = 0.004) CONCLUSIONS: NRF-1 is involved in the development of breast cancer and its correlation with Ki-67 expression. It can be used as an indicator of disease progression and prognosis in breast cancer patients, and may be a new therapeutic target for breast cancer.